1-6 of 6
Elizabeth M. Swisher
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

Shogo Shigeta, Goldie Y.L. Lui, Reid Shaw, Russell Moser, Kay E. Gurley, Grace Durenberger, Rachele Rosati, Robert L. Diaz, Tan A. Ince, Elizabeth M. Swisher, Carla Grandori, Christopher J. Kemp
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (4): 691–703.
https://doi.org/10.1158/1535-7163.MCT-20-0809
Published: 01 April 2021
View article titled, Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
Open the PDF for Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations

Pyoung Hwa Park, Tomomi M. Yamamoto, Hua Li, Allen L. Alcivar, Bing Xia, Yifan Wang, Andrea J. Bernhardy, Kristen M. Turner, Andrew V. Kossenkov, Zachary L. Watson, Kian Behbakht, Silvia Casadei, Elizabeth M. Swisher, Paul S. Mischel, Neil Johnson, Benjamin G. Bitler
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (2): 602–613.
https://doi.org/10.1158/1535-7163.MCT-17-0256
Published: 06 February 2020
View article titled, Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations
Open the PDF for Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations in another window
Includes: Supplementary data
Journal Articles

Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer

Joyce F Liu, Su-Chun Cheng, Robert M Wenham, Andrea E Wahner Hendrickson, Deborah K Armstrong, Nancy Chan, David E Cohn, Jung-Min Lee, Richard T Penson, Mihaela Cristea, James Abbruzzese, Koji Matsuo, Alexander B Olawaiye, Jennifer Curtis, Geoffrey Shapiro, Ursula A Matulonis, Elise Kohn, Percy Ivy, Elizabeth M Swisher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A074.
https://doi.org/10.1158/1535-7163.TARG-19-A074
Published: 01 December 2019
View article titled, Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer
Journal Articles

Abstract LB-A12: Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive high-grade ovarian carcinoma

David M. O'Malley, Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Iain A. McNeish, Elizabeth M. Swisher, Clare L. Scott, Gottfried E. Konecny, Heidi Giordano, Terri Cameron, Lara Maloney, Sandra Goble, James Sun, Thomas C. Harding, Kevin K. Lin, Jonathan A. Ledermann
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-A12.
https://doi.org/10.1158/1535-7163.TARG-17-LB-A12
Published: 01 January 2018
View article titled, Abstract LB-A12: Results from the phase 3 study ARIEL3: mutations in non-<em>BRCA</em> homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive high-grade ovarian carcinoma
Journal Articles

Abstract PR05: An assessment of the prognostic and predictive associations of 13 angiogenic biomarkers in women with newly diagnosed advanced ovarian cancer treated with chemotherapy with or without bevacizumab

Wei Wei, Mark F. Brady, Tsun-Yee Tsang, Vinod Vathipadiekal, Robert A. Burger, Robert S. Mannel, Parviz Hanjani, Warner K. Huh, Elizabeth M. Swisher, Thomas J. Rutherford, Janos L. Tanyi, Julian C. Schink, Shashikant B. Lele, Paul A. DiSilvestro, Michael J. Birrer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_1): PR05.
https://doi.org/10.1158/1538-8514.TUMANG15-PR05
Published: 01 December 2015
View article titled, Abstract PR05: An assessment of the prognostic and predictive associations of 13 angiogenic biomarkers in women with newly diagnosed advanced ovarian cancer treated with chemotherapy with or without bevacizumab
Journal Articles

Abstract C74: Stabilization of mutant BRCA1 confers PARP inhibitor and platinum resistance.

Neil Johnson, Shawn F. Johnson, Yifan Wang, Andrea Bernhardy, Wei Yao, Young-Eun Choi, Marzia Capelletti, Kristopher Sarosiek, Lisa Moreau, Dipanjan Chowdhury, Joyce Liu, Alan D'Andrea, Alexander Miron, Anneka Wickramanayake, Maria Harrell, Elizabeth M. Swisher, Geoffrey I. Shapiro
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C74.
https://doi.org/10.1158/1535-7163.TARG-13-C74
Published: 01 November 2013
View article titled, Abstract C74: Stabilization of mutant BRCA1 confers PARP inhibitor and platinum resistance.